Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone908-443-1860
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/9/2019 (Estimated)
OptionableNot Optionable
Matinas Biopharma (NASDAQ:MTNB) Frequently Asked Questions
What is Matinas Biopharma's stock symbol?
Matinas Biopharma trades on the NASDAQ under the ticker symbol "MTNB."
How were Matinas Biopharma's earnings last quarter?
Matinas Biopharma Holdings, Inc. (NASDAQ:MTNB) released its earnings results on Monday, May, 13th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.01. View Matinas Biopharma's Earnings History.
When is Matinas Biopharma's next earnings date?
What is the consensus analysts' recommendation for Matinas Biopharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Matinas Biopharma.
Has Matinas Biopharma been receiving favorable news coverage?
Media coverage about MTNB stock has been trending very positive this week, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Matinas Biopharma earned a news sentiment score of 3.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Matinas Biopharma's key competitors?
Some companies that are related to Matinas Biopharma include Emerald Health Therapeutics (EMH), Starpharma (SPL), Biotest (BIO), Oxford BioMedica (OXB), Neptune Wellness Solutions (NEPT), Theratechnologies (TH), Senesco Technologies (ELOX), Kodiak Sciences (KOD), Monash IVF Group (MVF), IMV (IMV), Paradigm Biopharmaceuticals (PAR), 22nd Century Group (XXII), Horizon Discovery Group (HZD), Emblem (EMC) and Enochian Biosciences (ENOB).
What other stocks do shareholders of Matinas Biopharma own?
Who are Matinas Biopharma's key executives?
Matinas Biopharma's management team includes the folowing people:
- Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 45)
- Mr. Keith A. Kucinski CPA, Chief Financial Officer (Age 48)
- Dr. Raphael J. Mannino, Sr. VP & Chief Scientific Officer (Age 72)
- Dr. Theresa Matkovits, Chief Devel. Officer (Age 52)
- Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply Chain
How do I buy shares of Matinas Biopharma?
Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Matinas Biopharma's stock price today?
One share of MTNB stock can currently be purchased for approximately $0.9882.
How big of a company is Matinas Biopharma?
Matinas Biopharma has a market capitalization of $141.25 million.
What is Matinas Biopharma's official website?
How can I contact Matinas Biopharma?
The company can be reached via phone at 908-443-1860.
MarketBeat Community Rating for Matinas Biopharma (NASDAQ MTNB)
MarketBeat's community ratings are surveys of what our community members think about Matinas Biopharma and other stocks. Vote "Outperform" if you believe MTNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTNB will underperform the S&P 500 over the long term. You may vote once every thirty days.
